Featured Research

from universities, journals, and other organizations

Lithium Protects Brain Cells During Cranial Radiation

Date:
April 1, 2009
Source:
Journal of Clinical Investigation
Summary:
Cranial radiation therapy to treat brain cancer can result in various long-term neurological side effects, particularly in children. New research, generated in mice, now indicates that lithium protects nerves in the region of the brain known as the hippocampus during irradiation by promoting DNA repair, leading to the suggestion that lithium should be considered as a possible treatment to reduce the long-term neurological side effects of cranial radiation therapy, particularly in children.

Cranial radiation therapy to treat brain cancer can result in various long-term neurological side effects, particularly in children. Lithium has protective properties in the brain that make it a potential therapy for reducing these side effects; however, little is known about the mechanisms by which it protects nerves.

In a new study, Fen Xia and colleagues, at Vanderbilt University Medical Center, Nashville, present results, generated in irradiated mice, that lithium protects nerves in the region of the brain known as the hippocampus by promoting DNA repair.

Specifically, a decreased number of double-strand DNA breaks were observed in lithium-treated, irradiated mice and brain cells compared to controls. This decrease was associated with increased markers for the nonhomologous end-joining DNA repair pathway.

When this pathway was blocked in mice, lithium provided substantially less protection to the hippocampal nerve cells. The authors therefore conclude that lithium should be considered as a possible treatment to reduce the long-term neurological side effects of cranial radiation therapy, particularly in children, and that targeted therapies to enhance DNA repair may provide an avenue for future therapeutic development.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Yang et al. Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PK–dependent repair in mice. Journal of Clinical Investigation, 2009; DOI: 10.1172/JCI34051

Cite This Page:

Journal of Clinical Investigation. "Lithium Protects Brain Cells During Cranial Radiation." ScienceDaily. ScienceDaily, 1 April 2009. <www.sciencedaily.com/releases/2009/04/090401181219.htm>.
Journal of Clinical Investigation. (2009, April 1). Lithium Protects Brain Cells During Cranial Radiation. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/04/090401181219.htm
Journal of Clinical Investigation. "Lithium Protects Brain Cells During Cranial Radiation." ScienceDaily. www.sciencedaily.com/releases/2009/04/090401181219.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins